Arformoterol
Clinical data | |
---|---|
Trade names | Brovana |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602023 |
License data |
|
Pregnancy category |
|
Routes of administration | Inhalation solution for nebuliser |
ATC code | none |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 52–65% |
Biological half-life | 26 hours |
Identifiers | |
| |
CAS Number | 67346-49-0 |
PubChem (CID) | 3083544 |
IUPHAR/BPS | 7479 |
DrugBank | DB01274 |
ChemSpider | 2340731 |
UNII | F91H02EBWT |
ChEBI | CHEBI:408174 |
ChEMBL | CHEMBL1201137 |
Chemical and physical data | |
Formula | C19H24N2O4 |
Molar mass | 344.405 g/mol |
| |
(what is this?) (verify) |
Arformoterol is a long-acting β2 adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.[1]
It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.
References
- ↑ "Brovana Prescribing information, Dosage and Administration section". Archived from the original on 13 February 2008. Retrieved 2008-03-14.
External links
- Brovana website
This article is issued from Wikipedia - version of the 9/10/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.